Observational studyBMC pregnancy and childbirth2025
The added value of the sFlt-1/PlGF ratio in pregnant women with intrauterine growth restriction (IUGR) with or without preeclampsia on adverse pregnancy outcomes and neonatal morbidities: a retrospective study.
Observational study in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- sFlt-1/PlGF Ratio as a Central Biomarker for Preeclampsia and Perinatal Outcomes: A Multisystem Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Development and internal validation of a nomogram for predicting adverse pregnancy outcomes in women with early-onset preeclampsia.Frontiers in medicine · 2026Article
- Placental dysfunction drives fetal growth restriction: mechanisms and translational perspectives.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe sFlt-1/PlGF (soluble fms-like tyrosine kinase-1/placental growth factor) ratio in serum of pregnant women is a predictive marker for preeclampsia (PE). PE is often associated with intrauterine growth restriction (IUGR). Overall, growth-restricted fetuses are at increased risk for neonatal morbidities and perinatal death. An increased sFlt-1/PlGF ratio may be valuable for discriminating between different causes of IUGR. The goal of this study is to investigate the added value of the sFlt-1/PlGF ratio in pregnant women with IUGR on adverse pregnancy outcomes, neonatal morbidities and mortality.
methodsThis was a retrospective, monocenter, observational study conducted at the University Hospital of Antwerp. All singleton pregnancies with IUGR and known serum levels of sFlt-1/PlGF with a gestational age of 24 weeks until 37 weeks were included. The results were analyzed over a period of almost three years (January 2022 until October 2024). In total, 85 patients met the inclusion criteria, ten of whom had not raised serum levels of sFlt-1/PlGF (values less than 85), whereas the other 75 patients had increased sFlt-1/PlGF ratios. The maternal characteristics, fetal and neonatal mortality rates, adverse pregnancy outcomes and neonatal morbidities of all the patients and their neonates were recorded and analyzed.
resultsIn IUGR fetuses with increased maternal serum sFlt-1/PlGF ratios, aberrant ultrasonic fetal doppler, fetal demise and obstetrical diseases such as PE are more often observed. In the group of neonates from mothers with a raised sFlt-1/PlGF ratio, more neonatal morbidities, such as respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, early-onset sepsis, late-onset sepsis and retinopathy of prematurity, are observed. Nevertheless, it is important to correct those results for GA and birth weight since morbidities are more often observed in more premature neonates.
conclusionIn patients with IUGR due to placental insufficiency, an increased sFlt-1/PlGF ratio is observed. Only in the group with an increased sFlt-1/PlGF ratio did intrauterine fetal death occur. During pregnancy, more obstetrical diseases and a greater need for medication were observed. Neonatal outcomes always need to be corrected for GA and birth weight, but therefore, the inclusion number was too low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.